| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1366205 | Bioorganic & Medicinal Chemistry Letters | 2007 | 5 Pages |
Abstract
We designed several HIV protease inhibitors with various d-cysteine derivatives as P2/P3 moieties based on the structure of clinical drug candidate, KNI-764. Herein, we report their synthesis, HIV protease inhibitory activity, HIV IIIB cell inhibitory activity, cellular toxicity, and inhibitory activity against drug-resistant HIV strains. KNI-1931 showed distinct selectivity against HIV proteases and high potency against drug-resistant strains, surpassing those of Ritonavir and Nelfinavir.
Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slide
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Ei’ichi Ami, Koichiro Nakahara, Akihiko Sato, Jeffrey-Tri Nguyen, Koushi Hidaka, Yoshio Hamada, Shingo Nakatani, Tooru Kimura, Yoshio Hayashi, Yoshiaki Kiso,